Member Info for inanaco

https://www.researchandmarkets.com/research/sw7ccn/the_65_bn?w=12

Keytruda in melanoma is not the complete story is it ... what about Opdivo ?

surely if you are looking at a specific market you have to include all checkpoints approved ...

you missed the Point Ruck

Happy to buy at 15p
Happy to buy at 10p

yet you won't buy now ...

yet the science today is even more impressive as the peer reviewed papers are presented ... and you now have Homocitrulline and avidmab ,....

what has made you change your mind ... or has the science presented just passed over your head

well actually its worse ........wild

this is a personal vaccine ........ not a universal ... tailored specific to the patient .... to make it commercial you would need success rates of 50% or above .... to cover the costs ...

MRNA .... opps

But what i will do is make it simple for you ...

2017 you bought at 15p approx 13,000
2018 you bought at 10p approx 60,000

i do not know how many you had bought prior ...

....... Today Mcap is £27m

Invested capital in scancells pipeline exceeds that ....

we all know how efficient Scancell is compared with say Inovio ... ie they have blown $500m

Scancell invents in house ... or from within the Campus of which all the scientific papers even from Trent still carry "lindy Durrant" in the title

if you wanted to find a target ..... lets say you pay BioNtech ........... you would probably get a couple of epitopes for £27m

this market has no idea of the costs involved with discovery ....

I am buying ...... I do ...

Ruck Rover ..........

you now want to debate and question Further ... despite posting just

"""" Mix these together and it becomes an impossible debate."""

do us all a favor and work it out yourself .. i really have no interest in your posts

Scale mate ..........

Scancell also has that scalability for single developed vaccine that is universal across multiple cancer types thus modi1 for 4 targets so far ... but we actually know that could be higher as they keep changing the 4 primary ..

we have the ability to combine vaccines .... adding Modi2 to further increase targets and efficacy in cancers expressing Vementin

The market is constantly moving towards us .. ie the check point developers are trying to improve efficacy by further control on the micro environment within the cancer

we can potentially treat cancers that the Check points have no effect on .... (failed trials prove that)

if you work out the potential of moditope................. it dwarfs Checkpoints ...

Question What is the estimated percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor drugs approved for oncology indications by the US Food and Drug Administration?

Findings This cross-sectional study found that the estimated percentage of US patients with cancer who are eligible for checkpoint inhibitor drugs increased from 1.54% in 2011 to 43.63% in 2018. The percentage of patients estimated to respond to checkpoint inhibitor drugs was 0.14% in 2011 and increased to 12.46% in 2018.

Meaning The estimated percentages of patients who are eligible for and who respond to checkpoint inhibitor drugs are higher than reported estimates for drugs approved for genome-driven oncology but remain modest.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2732329

Keytruda (pembrolizumab) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.

Keytruda is used alone or in combination with other medicines to treat certain types of cancer such as:

advanced skin cancer (melanoma or Merkel cell carcinoma);

lung cancer;

small cell lung cancer;

head and neck cancer;

classical Hodgkin lymphoma in adults and children;

primary mediastinal large B-cell lymphoma;

cancer of the kidney, bladder, and urinary tract;

liver;

cancer of the cervix or uterus;

advanced stomach cancer if your tumor tests positive for "PD-L1" and has a specific genetic marker (an abnormal "HER2/neu" gene);

a type of cancer called squamous cell carcinoma of the esophagus;

a type of liver cancer called hepatocellular carcinoma, after you have received the medicine sorafenib;

a type of kidney cancer called renal cell carcinoma (RCC) when used in combination with the medicine axitinib; or

a type of uterine cancer called endometrial carcinoma when used in combination with the medicine lenvatinib.

keytruda sales ...... $ 3 Billion a quarter .. ......... Fact

that will have them scratching heads ...

https://www.evaluate.com/vantage/articles/events/conferences/aacr-2020-biontech-and-roche-try-resuscitate-cancer-vaccines

then you best Tell that to keytruda .......

Dear Merck

I dont think your keytruda locks on to all CD8's that have the ligand

sign NoN expert Ruck

reply ...

Then why do we have systemic toxicity ....

Sign ... £12b of sales proves it

Accountant

SCIB1 has already been in trial ... he is talking about Covid ...

agree ....

But we cant buy the share with the results ................. Ruck !!!! today ...... but if you can predict success from the science ...

different story ......... 6p is the cheap ... i am still buying while sadly you are not onboard with buying at this level ATB

RuckRover

Posts: 2,827

Price: 6.10

No Opinion

RE: UpdateToday 13:16
“just some cannot accept that the "synergy" exists without proof ”
Too true, including the whole scientific community, medical profession and the regulatory authorities.
Now where’s that first patient dosed?

the point is Ruck .......... my predictions on the science from readout of trial results and looking at the data ... turn out to be correct .........

and your claim to fame is ... Good lad £10 a share

14/4/2015
17:56 Wanderer1210, when Genexine announce there phase 2 trial results "short Inovio" wait for the signal . they awarded themselves best vaccine again ! lol go and look at Genexine, the vaccine is based on a Mab like scancells the results are astonishing, they actually compare the data so you should be able to follow it. Inovio announced a phase 1 first cohort of 4 patients in there neck cancer based around vgx3100 and il-12 vaccine, announcing a T cell response .. oh wow! read there phase one vgx3100 data t cell data compare it to what actually converted to benefit in the phase 2 if you want to make money .. understand the science GOOD luck

i posted this on ADFVN .... in 2016

18/11/2016
17:32 About two years ago i gave folks the run down on Genexine, describing the vaccine as potent and the only company to get close to Scancell in quality of the science in this area. the posts are all there to see, hxxp://www.fiercepharma.com/pharma/merck-joins-genexine-to-test-keytruda-cancer-vaccine-combo Time ..... that all this is, deals will be done

Bunsie ........... any Vaccine that works with a Checkpoint is the jewel in the crown ....

SCIB1 has the data so its Scancells bed rock

it alone can command the sort of values that would transform the SP ... and you have the data that shows it ...

just some cannot accept that the "synergy" exists without proof

Despite trial after trial showing good vaccine do induce Synergy with a check point

Now both Wild and Bermuda should acknowledge that i thought Inovios Vaccine for HPV was Poor ,, and i considered Genexines Vaccine superior .... about 5 years ago

Genexines vaccine with keytruda is now producing excellent results

Scib1 "Will" do the same ....

no mechanism has appeared to show how it could fail ...... i can't find one .. """" only evidence that it will work """"

you have the jewel already

and CRUK agreed

thats is not the Fun bit Ruck ................. what will lozan do ? he has to explain that i was cautious at £8 and you was the reckless hyper at £10 ...

Tosh will go into melt down...